We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?
Read MoreHide Full Article
Key Takeaways
DefenCath is CRMD's main growth driver, launched across inpatient and outpatient settings in 2024.
DefenCath's sales in Q3 are expected to have been driven by strong uptake in the U.S. market.
Melinta's $300M acquisition brings seven drugs, expanding CRMD's hospital and infection care portfolio.
CorMedix’s (CRMD - Free Report) DefenCath (Taurolidine + Heparin) is its lead marketed product and the primary revenue driver for the company. The FDA approved DefenCath in late 2023 as the first and only antimicrobial catheter lock solution in the United States. The drug is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSIs) in adult patients with kidney failure who receive chronic hemodialysis through a central venous catheter. The product was commercially launched in April 2024 in the inpatient setting and in July 2024 in the outpatient hemodialysis setting. Investors will be most keen to know the sales numbers of this drug when CRMD reports third-quarter results.
DefenCath occupies a distinctive market position as the only FDA-approved therapy for a niche indication, with patent protection extending through 2033. CorMedix’s revenues in the third quarter of 2025 are expected to be driven by strong market adoption, suggesting significant year-over-year growth, and accounting for most of the company’s total revenues.
CRMD recently took a significant step toward diversifying its revenues and reducing reliance on DefenCath with the $300 million acquisition of Melinta Therapeutics. This move added seven approved therapies to its portfolio, strengthening its presence in hospital acute care and infectious disease markets. The expanded portfolio not only broadened the company’s revenue base but also created near-term growth opportunities, particularly for Rezzayo, which is being evaluated in a phase III study for prophylaxis of invasive fungal infections, with potential label expansion in 2026.
These acquired products from Melinta are anticipated to generate incremental revenues in the third quarter, contributing meaningfully to the company’s top-line growth. The Zacks Consensus Estimate for CorMedix’s total revenues in the third quarter of 2025 is currently pegged at $69.55 million.
Other Companies That Market Heparin
DefenCath combines taurolidine, an antimicrobial agent, with the anticoagulant heparin in a fixed-dose formulation designed for a niche population of kidney failure patients. While CorMedix currently enjoys a first-mover advantage in the United States with no direct competitors in CRBSI prevention, the competitive landscape carries risks. Larger players, such as Pfizer (PFE - Free Report) , Amphastar Pharmaceuticals (AMPH - Free Report) , B. Braun, Baxter and Fresenius Kabi USA LLC, already market heparin across a range of indications in the United States. With their deeper pipelines, manufacturing scale and financial resources, these companies could quickly emerge as formidable rivals if they choose to pursue CRBSI-specific applications, potentially eroding CorMedix’s market exclusivity and long-term growth prospects.
Pfizeralready markets Heparin Sodium Injection, an anticoagulant with broad clinical applications ranging from the treatment of venous thrombosis and pulmonary embolism to use in surgery, dialysis, and transfusion settings. Backed by its global scale, extensive clinical infrastructure and financial resources, Pfizer could quickly pivot to CRBSI-specific indications, posing a significant challenge to CorMedix’s foothold.
AmphastarPharmaceuticalscurrentlymarkets Enoxaparin, a complex low molecular weight heparin with multiple indications. AMPH controls its entire supply chain by producing the active pharmaceutical ingredient in-house, giving it stronger cost efficiencies and quality oversight. This vertically integrated model, combined with Amphastar Pharmaceuticals’ manufacturing expertise, underscores the competitive risk for CorMedix if the company decides to extend its anticoagulant capabilities into the CRBSI market targeted by DefenCath.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?
Key Takeaways
CorMedix’s (CRMD - Free Report) DefenCath (Taurolidine + Heparin) is its lead marketed product and the primary revenue driver for the company. The FDA approved DefenCath in late 2023 as the first and only antimicrobial catheter lock solution in the United States. The drug is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSIs) in adult patients with kidney failure who receive chronic hemodialysis through a central venous catheter. The product was commercially launched in April 2024 in the inpatient setting and in July 2024 in the outpatient hemodialysis setting. Investors will be most keen to know the sales numbers of this drug when CRMD reports third-quarter results.
DefenCath occupies a distinctive market position as the only FDA-approved therapy for a niche indication, with patent protection extending through 2033. CorMedix’s revenues in the third quarter of 2025 are expected to be driven by strong market adoption, suggesting significant year-over-year growth, and accounting for most of the company’s total revenues.
CRMD recently took a significant step toward diversifying its revenues and reducing reliance on DefenCath with the $300 million acquisition of Melinta Therapeutics. This move added seven approved therapies to its portfolio, strengthening its presence in hospital acute care and infectious disease markets. The expanded portfolio not only broadened the company’s revenue base but also created near-term growth opportunities, particularly for Rezzayo, which is being evaluated in a phase III study for prophylaxis of invasive fungal infections, with potential label expansion in 2026.
These acquired products from Melinta are anticipated to generate incremental revenues in the third quarter, contributing meaningfully to the company’s top-line growth. The Zacks Consensus Estimate for CorMedix’s total revenues in the third quarter of 2025 is currently pegged at $69.55 million.
Other Companies That Market Heparin
DefenCath combines taurolidine, an antimicrobial agent, with the anticoagulant heparin in a fixed-dose formulation designed for a niche population of kidney failure patients. While CorMedix currently enjoys a first-mover advantage in the United States with no direct competitors in CRBSI prevention, the competitive landscape carries risks. Larger players, such as Pfizer (PFE - Free Report) , Amphastar Pharmaceuticals (AMPH - Free Report) , B. Braun, Baxter and Fresenius Kabi USA LLC, already market heparin across a range of indications in the United States. With their deeper pipelines, manufacturing scale and financial resources, these companies could quickly emerge as formidable rivals if they choose to pursue CRBSI-specific applications, potentially eroding CorMedix’s market exclusivity and long-term growth prospects.
Pfizeralready markets Heparin Sodium Injection, an anticoagulant with broad clinical applications ranging from the treatment of venous thrombosis and pulmonary embolism to use in surgery, dialysis, and transfusion settings. Backed by its global scale, extensive clinical infrastructure and financial resources, Pfizer could quickly pivot to CRBSI-specific indications, posing a significant challenge to CorMedix’s foothold.
AmphastarPharmaceuticalscurrentlymarkets Enoxaparin, a complex low molecular weight heparin with multiple indications. AMPH controls its entire supply chain by producing the active pharmaceutical ingredient in-house, giving it stronger cost efficiencies and quality oversight. This vertically integrated model, combined with Amphastar Pharmaceuticals’ manufacturing expertise, underscores the competitive risk for CorMedix if the company decides to extend its anticoagulant capabilities into the CRBSI market targeted by DefenCath.